Biotech | November 18, 2021
Daiichi Sankyo initiates Phase 2 trial of mRNA Covid-19 vaccine in Japan
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Launching in 2022, its availability will be expanded to the global market
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
The company has operations in North America, Asia, and Europe,
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The consideration for the medicines in India is valued at Rs 180.48 crore
Cipla is a leading global pharma company
Subscribe To Our Newsletter & Stay Updated
